Skip to main content

Table 2 Main reported psoriasis-associated HDL alterations

From: Psoriasis-associated vascular disease: the role of HDL

Ref: number of subjects HDL alterations
Mehta (42): 112 patients Reduced cholesterol efflux capacity
Holzer (35): 15 patients Reduced cholesterol efflux capacity
Reduced apoA-I, apoA-II, apoM
Reduced phospholipid (phosphatidylcholine and sphingomyeline) and cholesterol content
Increased SAA, prothrombin, α-1-anti-trypsine, α-1-acid-glycoprotein 1
Not altered PON-1 activity
Holzer (51): 15 patients Reduced cholesterol efflux capacity
Reduced apoA-I and apoM
Reduced phospholipid (phosphatidylcholine and sphingomyeline) and cholesterol content
Increased SAA, prothrombin, α-1anti-trypsine, α-1-acid glycoprotein 1
Reduced PON-1 activity
He (44): 25 patients Reduced PON-1 activity
Reduced anti-inflammatory activity
Usta (45): 25 patients Reduced PON-1 activity
Ferretti (46): 23 patients Reduced PON-1 activity
Increased lipid peroxidation
Toker (20): 30 patients Increased PON-1 activity
Tom (43): 44 paediatric patients Reduced cholesterol efflux capacity
  1. HDL high-density lipoprotein, apoA-I apolipoprotein A-I, apo-A-II apolipoprotein A-II, apoM apolipoprotein M, SAA serum amyloid A, PON-1 paraoxonase 1